Analysis of short-term efficacy and adverse reactions of dolutegravir sodium,abacavir sulfate and lamivudine tablets in the treatment of HIV infection
Objective To investigate the efficacy and adverse drug reactions of dolutegravir sodium,abacavir sulfate and lamivudine tablets (trade name:Triumeq) in the treatment of human immunodeficiency virus (HIV) infection and provide guidance for its clinical application. Methods The clinical data of 69 patients diagnosed with HIV infection who initially received antiretroviral therapy (ART) with dolutegravir sodium,abacavir sulfate and lamivudine tablets were retrospectively analyzed,and the clinical efficacy and adverse reactions of the patients at 2,4 and 12 weeks of treatment were observed. Results Human immunodeficiency virus ribonucleic acid (HIV-RNA) of 69 patients at 4 weeks of treatment decreased significantly from (5.34±1.13)×log10 IU/ml before treatment to (1.88±0.76)×log10 IU/ml,and the difference was statistically significant (P<0.05);HIV-RNA at 12 weeks of treatment decreased to (1.75±0.76)×log10 IU/ml,and the difference was statistically significant (P<0.05) when compared with that before treatment. At 4 weeks of treatment,64 patients (92.8％) had HIV-RNA<200 copies/ml. CD+T lymphocyte counts rose to 118.0 (86.0,238.0) cells/μl at 4 weeks of treatment,and 172.0 (89.5,287.0) cells/μl at 12 weeks of treatment,and the difference was statistically significant (P<0.05) when compared with 66.5 (19.0,204.0) cells/μl before treatment. CD+T lymphocyte counts at 12 weeks of treatment were higher than that at 4 weeks of treatment,and the difference was statistically significant (P<0.05). CD4/CD8 was significantly higher at 12 weeks of treatment when compared with those before treatment and at 4 weeks of treatment,and the difference was statistically significant (P<0.05). The incidence of liver function abnormality at 4 weeks of treatment was 8.7％,which was significantly lower than 26.1％ before treatment,and the difference was statistically significant (P<0.05). The creatinine (Cr) levels at 2,4 and 12 weeks of treatment were higher than those before treatment,and the difference was statistically significant (P<0.05). Cr levels gradually decreased after 2 weeks of treatment,and there was no significant difference in the comparison of Cr levels at 2,4 and 12 weeks of treatment (P>0.05). The triglyceride (TG) and total cholesterol (TC) levels at 2,4 and 12 weeks of treatment were higher than those before treatment,and the high-density lipoprotein cholesterol (HDL-C) level was higher than that before treatment. The difference was statistically significant (P<0.05). Conclusion Dolutegravir sodium,abacavir sulfate and lamivudine tablets have the characteristics of highly efficient inhibition of HIV viral replication and rapid improvement of the immune response. Cr is observed to increase at the early stage of medication,but gradually decreases as time went on. Meanwhile,TC level has a tendency to rise with the extension of time.
Dolutegravir sodium,abacavir sulfate and lamivudine tabletsHuman immunodeficiency virusEfficacyAdverse reactions
万方数据
维普
